Microplastics Found in 84 Percent of Heart Attack Patients' Blood

Researchers at Sapienza University of Rome detected micro- and nanoplastics (MNPs) — synthetic solid particles spanning two distinct size classes: microplastics (smaller than 5 millimeters) and nanoplastics (submicron particles typically under 1 micrometer) — in the blood of 84 percent of patients actively experiencing a heart attack, compared to just 32 percent of patients with healthy coronary arteries, according to a study published July 15, 2026 in the European Heart Journal. The more counterintuitive finding sits inside that gap: smoking does not just damage lungs, it appears to function as a plastic-delivery system, making smokers six times more likely to carry these particles directly into the vessels that feed the heart. With cardiovascular disease remaining the leading cause of death in developed countries, a newly identified and potentially modifiable environmental risk factor demands immediate attention from clinicians, regulators, and patients alike.

What the Research Found

The study enrolled 61 patients across two Italian hospital sites: Sant'Andrea University Hospital in Rome and Azienda Ospedaliera Universitaria Integrata of Verona. Patients were divided into three clinical categories: those experiencing a STEMI (ST-segment elevation myocardial infarction), the most severe form of heart attack involving complete arterial blockage; those with CCS (chronic coronary syndromes), a category of stable but ongoing ischemic heart disease; and controls with normal coronary arteries presenting for unrelated diagnostic procedures.

MNP detection rates followed a clear gradient across severity. Among STEMI patients, 84 percent had detectable plastics in their blood. Among CCS patients, the figure was 40 percent. Among the control group, it was 32 percent. The dominant polymer identified was polyethylene (PE), the material used in packaging, shopping bags, and a wide range of consumer products, found in 97 percent of all MNP-positive patients.

Beyond detection rates, the study measured IL-6 and TNF-alpha, two pro-inflammatory cytokines (proteins that signal tissue stress and immune activation). Both markers reached their highest concentrations in STEMI patients, specifically within the coronary circulation -- the network of blood vessels supplying the heart muscle directly. Elevated cytokine levels tracked with the presence of detectable MNPs, suggesting a localized pro-inflammatory association between plastic particles and the most acute form of coronary disease.

The study was led by Emanuele Barbato, MD, PhD, Director of the Cardiology Unit at Sant'Andrea University Hospital and a professor at Sapienza University of Rome, with co-investigation by Pasquale Paolisso, MD, PhD, also at Sant'Andrea. Coronary MNP analysis was performed at the University of Campania "Luigi Vanvitelli". The paper was published in the European Heart Journal.

How the Science Works

The most striking finding in the data is what smoking does to MNP exposure. Patients who smoked were six times more likely to have detectable microplastics in their blood than non-smokers. When the researchers combined smoking history with high PM2.5 exposure (fine particulate air pollution with particles no larger than 2.5 micrometers in diameter), the rate reached 100 percent: every patient who smoked and lived in a high-pollution environment had detectable plastics in their blood. Among non-smokers in low air-pollution environments, the figure dropped to 12.5 percent.

Air pollution exposure was not measured as a single-day snapshot. The research team collected PM2.5 data from each patient on the day of their angiography procedure and tracked their exposure retrospectively over the preceding two years, building an individual environmental exposure profile for each participant.

The proposed biological mechanism focuses on the lungs as the primary entry point. The authors hypothesize that tobacco smoke inhalation increases lung tissue permeability in ways that facilitate the transport of inhaled plastic particles from the airways into the bloodstream. Air pollution may operate through a similar pathway.

Paolisso described the broader context: "Micro and nanoplastics are tiny plastic particles that are found virtually everywhere in the environment, including the air we breathe, the water we drink, and many foods we consume. In recent years, scientists have begun to detect these particles in human tissues and organs, raising concerns about their potential health effects."

MNPs were sampled from both coronary blood, drawn directly from the vessels supplying the heart, and peripheral blood drawn from elsewhere in the body. This in vivo coronary sampling goes beyond prior work, which was predominantly conducted in cell cultures or on tissue removed from the body.

What It Means for Patients

Barbato was direct about what the data can and cannot support: "These findings do not prove that microplastics cause heart attacks, but they reveal a strong association between environmental exposures, microplastics in the blood and cardiovascular disease. In our study, smoking history was strongly linked to microplastics in the blood. Our findings suggest that smoking might make it easier for micro and nanoplastics to enter the blood stream via the lungs. Air pollution may act in a similar way."

The distinction between association and causation matters clinically. Observational studies of this design can identify patterns; they cannot establish that removing plastic exposure would reduce heart attack rates. The patients who had detectable MNPs also tended to be those with more severe disease, which means the correlation could partly reflect confounding variables not captured in the study.

What the findings do support is a reframing of smoking's risks. The traditional cardiovascular case against smoking centers on nicotine's effects on blood pressure and heart rate, and on combustion byproducts that damage arterial walls. This study adds a third mechanism: the pulmonary uptake of environmental plastic particles that then circulate through the coronary vessels, where they appear to be associated with elevated inflammatory markers in acute heart attack patients.

The practical implication for patients is contained in Barbato's policy statement: "The results highlight the need to consider microplastic pollution as part of the broader environmental determinants of health. Policies that reduce air pollution, tobacco exposure, and environmental plastic contamination could have benefits that extend beyond environmental protection and potentially improve cardiovascular health." Smoking cessation and reduced air pollution exposure are already recommended for heart health; this study suggests those recommendations may carry plastic-reduction benefits as well.

Competitive Landscape

No directly comparable commercial peers were publicly identifiable at publication time in the MNP cardiovascular diagnostics space. The relevant competitive framing here is methodological and regulatory rather than commercial.

On the methodological side, this study advances a field that has been building through in vitro and ex vivo work. Prior evidence on MNPs and cardiovascular disease was generated predominantly in cell cultures and on removed tissue. The Sapienza/Verona team's in vivo coronary blood sampling in living patients represents a meaningful step forward in clinical translation. The authors describe MNPs as having shifted from "inert contaminants" to "biologically active pollutants contributing to the pathophysiology of cardiovascular diseases, particularly by promoting the development and progression of atherosclerotic plaques and potentially triggering adverse cardiovascular events."

On the regulatory side, the study exists in direct tension with the current U.S. Food and Drug Administration position, which reportedly holds that available evidence does not demonstrate that microplastic or nanoplastic levels detected in foods pose a risk to human health. The European Heart Journal publication deepens that gap by providing in vivo coronary data that was not available when existing regulatory positions were formed.

Andreas Daiber, PhD, of the University Medical Centre of the Johannes Gutenberg University in Mainz, authored an accompanying editorial. Daiber and co-authors wrote that "the convergence of epidemiological, clinical, and mechanistic evidence suggests that plastic pollution may represent a previously underestimated cardiovascular risk factor." The editorial frames the finding within the broader concept of the exposome (the totality of environmental exposures an individual accumulates over a lifetime): "Individuals are exposed to multiple environmental stressors simultaneously, including air pollution, noise, chemical contaminants, plastics, and climate-related stressors, especially in the urban setting. These exposures may interact through shared biological pathways, leading to additive or synergistic effects on cardiovascular risk."

Matthew Campen of the University of New Mexico offered broader context: "We are seeing more and more studies corroborating that higher levels of plastics equals worse disease."

The Road to Clinic

The study carries several limitations its authors acknowledge. The total patient cohort was 61 individuals across three groups, a sample size that limits statistical power and the ability to control for confounding variables. Patient demographics including age, sex, body mass index, and dietary patterns are not reported in the available data, any of which could independently influence both MNP exposure levels and cardiovascular disease severity.

The detection methodology also raises an unanswered question: the study appears to report MNP presence as binary -- present or absent -- rather than as a quantified concentration. Without dose-response data, it is not possible to determine whether patients with higher MNP loads face proportionally greater cardiovascular risk, or whether there is a threshold effect below which plastic particles appear clinically inert.

The causal direction of the inflammation finding is also unresolved. Elevated IL-6 and TNF-alpha levels in MNP-positive STEMI patients could reflect plastics triggering inflammation, or diseased coronary tissue being more susceptible to plastic accumulation, or both simultaneously. Mechanistic studies in animal models or in vitro systems will be needed to trace the pathway.

Moving this finding toward clinical guidance would require a larger prospective cohort with full demographic controls, a longitudinal arm tracking whether smoking cessation reduces MNP blood levels over time, mechanistic proof of the pulmonary entry pathway, and data on whether MNPs concentrate in arterial plaque versus circulating blood. Each step represents years of research.

What's Next

Sapienza University of Rome and the University of Verona are positioned as natural lead institutions for follow-on work, given their established patient cohorts and coronary sampling infrastructure. The most immediate research priorities are quantifying MNP concentrations rather than merely detecting presence, and determining whether coronary blood carries higher MNP loads than peripheral blood in the same patient.

The authors describe MNPs, PM2.5, and smoking as "potentially modifiable environmental risk factors for cardiovascular diseases, with significant implications for public health and cardiovascular disease prevention." That framing positions plastic pollution alongside tobacco and air pollution as a target for public health intervention, even before causation is established, on the grounds that the exposure is real, the association with disease severity is measurable, and the mitigation levers are already partially deployed for other reasons.

The Daiber editorial places the finding in a longer arc: "In the era of the Anthropocene, protecting cardiovascular health will increasingly depend on reducing not only traditional risk factors but also the growing burden of environmental pollutants (the detrimental part of the exposome), among which plastics may soon play a central role." The cardiology field appears to be moving toward a model in which environmental exposure history is taken as seriously as cholesterol levels or blood pressure in assessing individual risk.

For a patient who smokes and lives in a high-pollution urban area: this study suggests that 100 percent of people fitting that profile had detectable plastic particles in their blood, versus 12.5 percent of non-smoking, low-pollution counterparts. Quitting smoking is already the single highest-impact cardiovascular intervention available to individual patients; this research adds a specific, mechanistic reason to expect that cessation reduces more than nicotine exposure.

-- Zara Velez, Emerging Technology Editor

Sources: GEN Biotechnology, July 15, 2026 · PMC / National Institutes of Health

Microplastics Found in 84 Percent of Heart Attack Patients' BloodMicroplastics Found in 84 Percent of Heart Attack Patients' BloodMicroplastics Found in 84 Percent of Heart Attack Patients' BloodMicroplastics Found in 84 Percent of Heart Attack Patients' Blood